Simpson v. Young’s Empirical Analysis

Citation profile

1 federal appellate ·

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 2 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

1. “subchronic range-finding study. See Red Book at 58, 120, J.A. at 84, 87. These studies are shorter in duration and use fewer animals than the full-fledged carcinogenicity studies, but are adequate to indicate the lowest dose at which minimal toxicity appears. Although petitioners concede that Red Book assertions are not binding on the agency, they contend that this document sets forth the agency's internal guidelines and that these guidelines are in accordance with”

   1 later decision quote this exact passage · from the majority
   e.g. Simpson v. Young

2. “on the basis of the results of the long-term carcinogenicity studies. 48 Fed.Reg. 5,252 (Feb. 4, 1983). Petitioners filed objections to the FDA's decision claiming, among other things, that the concentration of Blue No. 2 administered in the CCMA rat study to those animals receiving the highest dosage was too low. According to a manual published in 1982 by the FDA Bureau of Foods known as the”

   1 later decision quote this exact passage · from the majority
   e.g. Simpson v. Young

3. “[t]he long term [CCMA] rat study showed increased spleen and liver weights and lower fasting glucose levels in the F1 [i.e. second generation] mature adults. There was also a reduction in body weight of the treated pups by approximately 15 percent at weaning [and p]up survival decreased in the mid and high dose groups.”

   1 later decision quote this exact passage · from the majority
   e.g. Simpson v. Young